FDA
-
-
-
-
-
-
-
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
-
-
-
-
-
-
-
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
-
-
-
-
-
-
-
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
-
-
-
-
-
-
-
Avadel receives $23 per share takeover bid from Lundbeck
-
-
-
-
-
-
-
Alkermes plc Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Alkermes plc Reports Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
Alkermes (ALKS) Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI
-
323,555 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

